DOP2019000169A - Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 - Google Patents
Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1Info
- Publication number
- DOP2019000169A DOP2019000169A DO2019000169A DO2019000169A DOP2019000169A DO P2019000169 A DOP2019000169 A DO P2019000169A DO 2019000169 A DO2019000169 A DO 2019000169A DO 2019000169 A DO2019000169 A DO 2019000169A DO P2019000169 A DOP2019000169 A DO P2019000169A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pyridazines
- pyridines
- imidazo
- pyrazole
- pde1 inhibitors
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000004892 pyridazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600784 | 2016-12-22 | ||
| DKPA201700404 | 2017-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000169A true DOP2019000169A (es) | 2019-07-31 |
Family
ID=60812077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000169A DOP2019000169A (es) | 2016-12-22 | 2019-06-18 | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10351561B2 (enExample) |
| EP (1) | EP3558988B1 (enExample) |
| JP (1) | JP7074758B2 (enExample) |
| KR (1) | KR20190095301A (enExample) |
| CN (1) | CN110099901B (enExample) |
| AU (1) | AU2017384481A1 (enExample) |
| BR (1) | BR112018017067A2 (enExample) |
| CA (1) | CA3046588A1 (enExample) |
| CL (1) | CL2019001669A1 (enExample) |
| CO (1) | CO2019005538A2 (enExample) |
| CR (1) | CR20190302A (enExample) |
| DO (1) | DOP2019000169A (enExample) |
| EC (1) | ECSP19043790A (enExample) |
| ES (1) | ES2882335T3 (enExample) |
| IL (1) | IL267561A (enExample) |
| JO (1) | JOP20190126A1 (enExample) |
| MX (1) | MX2019007509A (enExample) |
| PE (1) | PE20191323A1 (enExample) |
| PH (1) | PH12019501324A1 (enExample) |
| RU (1) | RU2019116251A (enExample) |
| TW (1) | TW201829405A (enExample) |
| WO (1) | WO2018115067A1 (enExample) |
| ZA (1) | ZA201904236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| CN115151550B (zh) * | 2019-12-23 | 2024-11-22 | 桑福德·伯纳姆·普雷比医学发现研究所 | 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| ES2319797T3 (es) * | 2004-07-05 | 2009-05-12 | Astellas Pharma Inc. | Derivados de pirazolopiridina. |
| US7652035B2 (en) | 2004-10-19 | 2010-01-26 | Neurocrine Bioscience, Inc. | CRF receptor antagonists and methods relating thereto |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN103497185A (zh) | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
| WO2009067607A2 (en) * | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| CN102223799A (zh) * | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
| JP6100883B2 (ja) | 2012-03-19 | 2017-03-22 | アビデ セラピューティクス，インク． | カルバマート化合物、及びその製造並びに使用 |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
-
2017
- 2017-06-16 JO JOP/2019/0126A patent/JOP20190126A1/ar unknown
- 2017-12-19 TW TW106144606A patent/TW201829405A/zh unknown
- 2017-12-20 AU AU2017384481A patent/AU2017384481A1/en not_active Abandoned
- 2017-12-20 CN CN201780079553.2A patent/CN110099901B/zh not_active Expired - Fee Related
- 2017-12-20 CR CR20190302A patent/CR20190302A/es unknown
- 2017-12-20 BR BR112018017067A patent/BR112018017067A2/pt not_active Application Discontinuation
- 2017-12-20 JP JP2019534197A patent/JP7074758B2/ja active Active
- 2017-12-20 ES ES17821622T patent/ES2882335T3/es active Active
- 2017-12-20 PE PE2019001294A patent/PE20191323A1/es unknown
- 2017-12-20 WO PCT/EP2017/083721 patent/WO2018115067A1/en not_active Ceased
- 2017-12-20 RU RU2019116251A patent/RU2019116251A/ru not_active Application Discontinuation
- 2017-12-20 CA CA3046588A patent/CA3046588A1/en not_active Abandoned
- 2017-12-20 MX MX2019007509A patent/MX2019007509A/es unknown
- 2017-12-20 EP EP17821622.2A patent/EP3558988B1/en active Active
- 2017-12-20 KR KR1020197017840A patent/KR20190095301A/ko not_active Ceased
- 2017-12-21 US US15/849,798 patent/US10351561B2/en active Active
-
2019
- 2019-05-28 CO CONC2019/0005538A patent/CO2019005538A2/es unknown
- 2019-05-29 US US16/424,585 patent/US10689379B2/en active Active
- 2019-06-11 PH PH12019501324A patent/PH12019501324A1/en unknown
- 2019-06-17 CL CL2019001669A patent/CL2019001669A1/es unknown
- 2019-06-18 DO DO2019000169A patent/DOP2019000169A/es unknown
- 2019-06-19 EC ECSENADI201943790A patent/ECSP19043790A/es unknown
- 2019-06-20 IL IL267561A patent/IL267561A/en unknown
- 2019-06-27 ZA ZA2019/04236A patent/ZA201904236B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017384481A1 (en) | 2019-06-13 |
| PH12019501324A1 (en) | 2019-09-16 |
| ES2882335T3 (es) | 2021-12-01 |
| JP2020502230A (ja) | 2020-01-23 |
| MX2019007509A (es) | 2019-09-04 |
| PE20191323A1 (es) | 2019-09-24 |
| RU2019116251A (ru) | 2021-01-22 |
| EP3558988A1 (en) | 2019-10-30 |
| US20190352302A1 (en) | 2019-11-21 |
| WO2018115067A1 (en) | 2018-06-28 |
| CN110099901A (zh) | 2019-08-06 |
| CN110099901B (zh) | 2023-01-03 |
| CO2019005538A2 (es) | 2019-06-11 |
| CR20190302A (es) | 2019-08-21 |
| TW201829405A (zh) | 2018-08-16 |
| CA3046588A1 (en) | 2018-06-28 |
| KR20190095301A (ko) | 2019-08-14 |
| JP7074758B2 (ja) | 2022-05-24 |
| CL2019001669A1 (es) | 2019-09-06 |
| IL267561A (en) | 2019-08-29 |
| US10689379B2 (en) | 2020-06-23 |
| ZA201904236B (en) | 2020-12-23 |
| EP3558988B1 (en) | 2021-07-07 |
| US10351561B2 (en) | 2019-07-16 |
| US20180179200A1 (en) | 2018-06-28 |
| ECSP19043790A (es) | 2019-06-30 |
| JOP20190126A1 (ar) | 2019-05-28 |
| RU2019116251A3 (enExample) | 2021-03-31 |
| BR112018017067A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000169A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 | |
| CO2018013803A2 (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1 | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| DOP2019000055A (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| SV2018005753A (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
| CL2020001550A1 (es) | Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas. | |
| CL2020001548A1 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas. | |
| ECSP14010000A (es) | Derivados de quinolina como inhibidores de la enzima pde10a | |
| EA201991062A1 (ru) | Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1 | |
| BR112017011335A2 (pt) | compostos de 4h-pirido[1,2-a]pirimidin-4-ona | |
| EA201892549A1 (ru) | ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1 |